Immunotherapy before surgery for stage II-IIIA squamous NSCLC
Part of Cancer, Lungs & breathing clinical trials.
This trial compares two immunotherapy drugs (serplulimab and nivolumab) given before surgery for people with resectable stage II-IIIA squamous non-small cell lung cancer. The goal is to see which works better to shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage II or stage IIIA squamous non-small cell lung cancer (confirmed by biopsy).
- Your doctor says you can safely have surgery to remove the lung tumor.
- You are in good physical condition (ECOG 0 or 1, meaning you are fully active or can do light work).
- You do not have certain gene changes (EGFR, ALK, ROS1), and your cancer has not spread to the brain or spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different drug combinations given before surgery for stage II-III non-small cell lung cancer (NSCLC). Both combinations include chemotherapy, and one also includes a newer type of immunotherapy. The goal is to see which approach shrinks tumors more effectively before surgery.
This trial compares giving immunotherapy before and after surgery versus only after surgery for people with early-stage but advanced lung cancer. It aims to see which timing might better help keep the cancer from coming back.
This trial tests an investigational drug called JSKN016 given before surgery to shrink non-small cell lung cancer tumors and improve outcomes. The goal is to see if this pre-treatment is safe and effective for patients with stage II-III disease that can be surgically removed.
This trial tests whether combining radiation, an immunotherapy drug (toripalimab), and chemotherapy before surgery can help shrink tumors and improve outcomes in people with resectable stage II to III non-small cell lung cancer. It aims to see if this approach works better than standard chemotherapy alone.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests whether two immunotherapy drugs (nivolumab and ipilimumab) given before surgery can help treat non-small cell lung cancer that is stage II to IIIA. It's for people whose tumors are removable and who haven't had prior cancer treatment.
Hear when a new Resectable Stage II-IIIa Squamous NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.